PKC’s lead product using several elements of the TumorFighter™ technology platform is the Metronomic Biofeedback Pump (MBP), which is expected to have initial applications in treatment of aggressive brain tumors such as malignant gliomas and other. Malignant gliomas are nearly always a death sentence for patients within one to two years of treatment. Although animal studies in mice with gliomas have demonstrated that extended delivery of medications using simple implantable pumps significantly increases survival, no implantable pumps have been developed for this purpose in humans. The MBP for local intratumoral drug delivery can potentially eliminate repeated brain surgery procedures, reduce the cost and enhance the effectiveness of tumor fighting medications while also improving patient quality of life and increasing patient survival.